<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02073487</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00010074</org_study_id>
    <secondary_id>1013-0164</secondary_id>
    <nct_id>NCT02073487</nct_id>
  </id_info>
  <brief_title>Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel</brief_title>
  <acronym>TEAL</acronym>
  <official_title>Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Methodist Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Methodist Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety&#xD;
      of trastuzumab emtansine (T-DM1) plus lapatinib (L)followed by abraxane (A) versus&#xD;
      trastuzumab plus pertuzumab followed by paclitaxel in patients with HER2-overexpressing&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open label Phase II neoadjuvant study comparing the efficacy and safety&#xD;
      of trastuzumab emtansine (T-DM1) plus lapatinib (L) followed by abraxane (A) versus&#xD;
      trastuzumab plus pertuzumab followed by paclitaxel in patients with HER2-overexpressing&#xD;
      breast cancer. Patients will be randomized (1:1) to one of the two treatment arms: arm 1,&#xD;
      trastuzumab emtansine plus lapatinib for 6 weeks, followed by trastuzumab emtansine plus&#xD;
      lapatinib plus abraxane for 12 weeks; arm 2, trastuzumab plus pertuzumab for six weeks,&#xD;
      followed by trastuzumab plus pertuzumab plus paclitaxel for 12 weeks. Patients will undergo&#xD;
      surgery after neoadjuvant therapy. All patients will have a core needle biopsy at baseline,&#xD;
      after week 6, and at the time of disease progression. Surgical specimens will be obtained&#xD;
      after week 18.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response (pCR) RCB-0 or RCB-1</measure>
    <time_frame>From date of randomization until the date of surgery, approximately 16 weeks</time_frame>
    <description>To evaluate the pathological complete response (pCR) in the breast after treatment with Trastuzumab Emtansine plus Lapatinib follow by Abraxane in women with HER2 Neu over-expressed breast cancer patients per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;, or similar definition that is accurate and appropriate.&#xD;
Residual cancer burden (RCB)-0 was synonymous with pCR, indicating no residual disease present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast Imaging Response to Treatment: Number of Eventual Responders in Standard Arm</measure>
    <time_frame>From date of randomization until 6 weeks post treatment</time_frame>
    <description>To determine the change in tumor size by MRI at 6 weeks post treatment using RECIST v1.0. Criteria. Since all patients in the experimental arm achieved RCB-0 or RCB-1 (pCR), changes in tumor size by MRI were only evaluated in patients on the standard arm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine Predictive Markers</measure>
    <time_frame>approximately 1 year</time_frame>
    <description>To determine predictive markers for sensitivity and resistance to Trastuzumab Emtansine when combined with Lapatinib follow by Abraxane</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>T-DM1 + Lapatinib + Abraxane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trastuzumab + Pertuzumab + Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>T-DM1</intervention_name>
    <description>antibody-drug conjugate of trastuzumab and emtansine</description>
    <arm_group_label>T-DM1 + Lapatinib + Abraxane</arm_group_label>
    <other_name>trastuzumab emtansine</other_name>
    <other_name>Kadcyla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>anti-Her2 monoclonal antibody</description>
    <arm_group_label>Trastuzumab + Pertuzumab + Paclitaxel</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lapatinib</intervention_name>
    <description>Dual tyrosine kinase inhibitor (HER2 and EGFR)</description>
    <arm_group_label>T-DM1 + Lapatinib + Abraxane</arm_group_label>
    <other_name>tykerb</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.</description>
    <arm_group_label>T-DM1 + Lapatinib + Abraxane</arm_group_label>
    <other_name>nab-paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>chemotherapy - microtubule inhibitor</description>
    <arm_group_label>Trastuzumab + Pertuzumab + Paclitaxel</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>anti-HER2 monoclonal antibody</description>
    <arm_group_label>Trastuzumab + Pertuzumab + Paclitaxel</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female gender;&#xD;
&#xD;
          -  Age ≥18 years;&#xD;
&#xD;
          -  Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1&#xD;
&#xD;
          -  Histologically confirmed invasive breast cancer:&#xD;
&#xD;
          -  Primary tumor greater than 1 cm diameter, measured by clinical examination and&#xD;
             mammography or ultrasound.&#xD;
&#xD;
          -  Any N,&#xD;
&#xD;
          -  No evidence of metastasis (M0) (isolated supra-clavicular node involvement allowed);&#xD;
&#xD;
          -  Over expression and/or amplification of HER2 in the invasive component of the primary&#xD;
             tumor and confirmed by a certified laboratory prior to randomization.&#xD;
&#xD;
          -  Known hormone receptor status.&#xD;
&#xD;
          -  Hematopoietic status:&#xD;
&#xD;
          -  CBC not less than .75 of institutional lower limit. Absolute neutrophil count ≥ 1,5 x&#xD;
             10^9/L, Platelet count ≥ 100 x 10^9/L, Hemoglobin at least 9 g/dl,&#xD;
&#xD;
          -  Hepatic status:&#xD;
&#xD;
        Serum total bilirubin ≤ 2 x upper limit of normal (ULN). In the case of known Gilbert's&#xD;
        syndrome, a higher serum total bilirubin (&lt; 1.5 x ULN) is allowed, Aspartate&#xD;
        Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤ 3.5 times ULN, Alkaline&#xD;
        phosphatase ≤ 2.5 times ULN, • Renal status: Creatinine ≤ 1.5mg/dL,&#xD;
&#xD;
        • Cardiovascular: Baseline left ventricular ejection fraction (LVEF) ³ ≥50% measured by&#xD;
        echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan,&#xD;
&#xD;
          -  Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing&#xD;
             potential within 2-weeks (preferably 7 days) prior to randomization.&#xD;
&#xD;
          -  Fertile patients must use effective contraception (barrier method - condoms, diaphragm&#xD;
             - also in conjunction with spermicidal jelly, or total abstinence. Oral, injectable,&#xD;
             or implant hormonal contraceptives are not allowed)&#xD;
&#xD;
          -  Signed informed consent form (ICF)&#xD;
&#xD;
          -  Patient accepts to make available tumor samples for submission to central laboratory&#xD;
             to conduct translational studies as part of this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous (less than 5 years) or current history of malignant neoplasms, except for&#xD;
             curatively treated: Basal and squamous cell carcinoma of the skin; Carcinoma in situ&#xD;
             of the cervix.&#xD;
&#xD;
          -  Patients with a prior malignancy diagnosed more than 5 years prior to randomization&#xD;
             may enter the study.&#xD;
&#xD;
          -  Preexisting peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  Known history of uncontrolled or symptomatic angina, clinically significant&#xD;
             arrhythmias, congestive heart failure, transmural myocardial infarction, uncontrolled&#xD;
             hypertension (≥180/110), unstable diabetes mellitus, dyspnea at rest, or chronic&#xD;
             therapy with oxygen;&#xD;
&#xD;
          -  Concurrent disease or condition that would make the subject inappropriate for study&#xD;
             participation or any serious medical disorder that would interfere with the subject's&#xD;
             safety;&#xD;
&#xD;
          -  Unresolved or unstable, serious adverse events from prior administration of another&#xD;
             investigational drug;&#xD;
&#xD;
          -  Dementia, altered mental status, or any psychiatric condition that would prevent the&#xD;
             understanding or rendering of ICF;&#xD;
&#xD;
          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel. Subjects with ulcerative colitis are also&#xD;
             excluded;&#xD;
&#xD;
          -  Concurrent neoadjuvant cancer therapy (chemotherapy, radiation therapy, immunotherapy,&#xD;
             biologic therapy other than the trial therapies);&#xD;
&#xD;
          -  Concurrent treatment with an investigational agent or participation in another&#xD;
             therapeutic clinical trial;&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to trastuzumab Emtansine, trastuzumab, lapatinib, paclitaxel,&#xD;
             abraxane or their components;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Concomitant use of CYP3A4 inhibitors or inducers&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.&#xD;
             active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable&#xD;
             safety risks or compromise compliance with the protocol&#xD;
&#xD;
          -  Patients have an active infection and require IV or oral antibiotics.&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Patients unwilling or unable to comply with the protocol&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny C Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Willowbrook</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital Sugar Land</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>February 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2014</study_first_posted>
  <results_first_submitted>March 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 22, 2021</results_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Methodist Hospital Research Institute</investigator_affiliation>
    <investigator_full_name>Jenny C. Chang, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant Breast Cancer</keyword>
  <keyword>HER2 positive Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Ado-Trastuzumab Emtansine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Lapatinib</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 23, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02073487/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>16 patients were enrolled into each arm of the study, for a total of 32 patients.&#xD;
The trial was closed early due to superiority, with 14 patients completing the experimental arm and 16 patients completing the standard, control arm.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>T-DM1 + Lapatinib + Abraxane</title>
          <description>T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.&#xD;
T-DM1: antibody-drug conjugate of trastuzumab and emtansine&#xD;
Lapatinib: Dual tyrosine kinase inhibitor (HER2 and EGFR)&#xD;
Abraxane: albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.</description>
        </group>
        <group group_id="P2">
          <title>Trastuzumab + Pertuzumab + Paclitaxel</title>
          <description>Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.&#xD;
Trastuzumab: anti-Her2 monoclonal antibody&#xD;
Paclitaxel: chemotherapy - microtubule inhibitor&#xD;
Pertuzumab: anti-HER2 monoclonal antibody</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>T-DM1 + Lapatinib + Abraxane</title>
          <description>T-DM1 intravenously (IV) every three weeks plus Lapatinib orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.&#xD;
T-DM1: antibody-drug conjugate of trastuzumab and emtansine&#xD;
Lapatinib: Dual tyrosine kinase inhibitor (HER2 and EGFR)&#xD;
Abraxane: albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.</description>
        </group>
        <group group_id="B2">
          <title>Trastuzumab + Pertuzumab + Paclitaxel</title>
          <description>Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.&#xD;
Trastuzumab: anti-Her2 monoclonal antibody&#xD;
Paclitaxel: chemotherapy - microtubule inhibitor&#xD;
Pertuzumab: anti-HER2 monoclonal antibody</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" lower_limit="27.8" upper_limit="69.7"/>
                    <measurement group_id="B2" value="57.2" lower_limit="39.6" upper_limit="74.9"/>
                    <measurement group_id="B3" value="55.1" lower_limit="27.8" upper_limit="74.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Invasive ductal carcinoma</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor grade: 2</title>
          <description>Size of primary tumor was measured at its widest point in centimeters and staged according to the American Cancer Society criteria:&#xD;
T0: The doctor has not found evidence of a primary tumor.&#xD;
T1: The tumor is 2 cm (0.79 inches (in)) or less in diameter.&#xD;
T2: The tumor is more than 2 cm (0.79 in) but less than 5 cm (1.97 in) across.&#xD;
T3: The tumor is larger than 5 cm (1.97 in) wide.&#xD;
T4: The tumor can be of any size, but it is growing into the chest wall or skin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor grade: 3</title>
          <description>Size of primary tumor was measured at its widest point in centimeters and staged according to the American Cancer Society criteria:&#xD;
T0: The doctor has not found evidence of a primary tumor.&#xD;
T1: The tumor is 2 cm (0.79 inches (in)) or less in diameter.&#xD;
T2: The tumor is more than 2 cm (0.79 in) but less than 5 cm (1.97 in) across.&#xD;
T3: The tumor is larger than 5 cm (1.97 in) wide.&#xD;
T4: The tumor can be of any size, but it is growing into the chest wall or skin.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor stage: II</title>
          <description>Staging Criteria:&#xD;
Stage 0: is for abnormal cells that haven't spread and are not considered cancer, though they could become cancerous in the future. This stage is also called &quot;in-situ.&quot; Stage I through Stage III: are for cancers that haven't spread beyond the primary tumor site or have only spread to nearby tissue. The higher the stage number, the larger the tumor and the more it has spread.&#xD;
Stage IV: cancer has spread to distant areas of the body.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tumor stage: III</title>
          <description>Staging Criteria:&#xD;
Stage 0: is for abnormal cells that haven't spread and are not considered cancer, though they could become cancerous in the future. This stage is also called &quot;in-situ.&quot;&#xD;
Stage I through Stage III: are for cancers that haven't spread beyond the primary tumor site or have only spread to nearby tissue. The higher the stage number, the larger the tumor and the more it has spread.&#xD;
Stage IV: cancer has spread to distant areas of the body.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathological Complete Response (pCR) RCB-0 or RCB-1</title>
        <description>To evaluate the pathological complete response (pCR) in the breast after treatment with Trastuzumab Emtansine plus Lapatinib follow by Abraxane in women with HER2 Neu over-expressed breast cancer patients per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;, or similar definition that is accurate and appropriate.&#xD;
Residual cancer burden (RCB)-0 was synonymous with pCR, indicating no residual disease present.</description>
        <time_frame>From date of randomization until the date of surgery, approximately 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>T-DM1 + Lapatinib + Abraxane</title>
            <description>T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.&#xD;
T-DM1: antibody-drug conjugate of trastuzumab and emtansine&#xD;
Lapatinib: Dual tyrosine kinase inhibitor (HER2 and EGFR)&#xD;
Abraxane: albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.</description>
          </group>
          <group group_id="O2">
            <title>Trastuzumab + Pertuzumab + Paclitaxel</title>
            <description>Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.&#xD;
Trastuzumab: anti-Her2 monoclonal antibody&#xD;
Paclitaxel: chemotherapy - microtubule inhibitor&#xD;
Pertuzumab: anti-HER2 monoclonal antibody</description>
          </group>
        </group_list>
        <measure>
          <title>Pathological Complete Response (pCR) RCB-0 or RCB-1</title>
          <description>To evaluate the pathological complete response (pCR) in the breast after treatment with Trastuzumab Emtansine plus Lapatinib follow by Abraxane in women with HER2 Neu over-expressed breast cancer patients per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.&quot;, or similar definition that is accurate and appropriate.&#xD;
Residual cancer burden (RCB)-0 was synonymous with pCR, indicating no residual disease present.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breast Imaging Response to Treatment: Number of Eventual Responders in Standard Arm</title>
        <description>To determine the change in tumor size by MRI at 6 weeks post treatment using RECIST v1.0. Criteria. Since all patients in the experimental arm achieved RCB-0 or RCB-1 (pCR), changes in tumor size by MRI were only evaluated in patients on the standard arm.</description>
        <time_frame>From date of randomization until 6 weeks post treatment</time_frame>
        <population>Since all patients in the experimental arm achieved RCB-0 or RCB-1 (pCR), changes in tumor size by MRI were only evaluated in patients on the standard arm. Of 16 patients enrolled in the standard arm, 5 had incomplete imaging data. Therefore, 11 patients were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Trastuzumab + Pertuzumab + Paclitaxel</title>
            <description>Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.&#xD;
Trastuzumab: anti-Her2 monoclonal antibody&#xD;
Paclitaxel: chemotherapy - microtubule inhibitor&#xD;
Pertuzumab: anti-HER2 monoclonal antibody</description>
          </group>
        </group_list>
        <measure>
          <title>Breast Imaging Response to Treatment: Number of Eventual Responders in Standard Arm</title>
          <description>To determine the change in tumor size by MRI at 6 weeks post treatment using RECIST v1.0. Criteria. Since all patients in the experimental arm achieved RCB-0 or RCB-1 (pCR), changes in tumor size by MRI were only evaluated in patients on the standard arm.</description>
          <population>Since all patients in the experimental arm achieved RCB-0 or RCB-1 (pCR), changes in tumor size by MRI were only evaluated in patients on the standard arm. Of 16 patients enrolled in the standard arm, 5 had incomplete imaging data. Therefore, 11 patients were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Determine Predictive Markers</title>
        <description>To determine predictive markers for sensitivity and resistance to Trastuzumab Emtansine when combined with Lapatinib follow by Abraxane</description>
        <time_frame>approximately 1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of informed consent through 30 days after the last treatment dose.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T-DM1 + Lapatinib + Abraxane</title>
          <description>T-DM1 intravenously (IV) every three weeks plus L orally once daily for 6 weeks followed by abraxane IV weekly for 12 weeks.&#xD;
T-DM1: antibody-drug conjugate of trastuzumab and emtansine&#xD;
Lapatinib: Dual tyrosine kinase inhibitor (HER2 and EGFR)&#xD;
Abraxane: albumin-bound paclitaxel. chemotherapy - microtubule inhibitor.</description>
        </group>
        <group group_id="E2">
          <title>Trastuzumab + Pertuzumab + Paclitaxel</title>
          <description>Trastuzumab IV weekly plus pertuzumab IV every 3 weeks for 6 weeks, followed by paclitaxel IV weekly for 12 weeks.&#xD;
Trastuzumab: anti-Her2 monoclonal antibody&#xD;
Paclitaxel: chemotherapy - microtubule inhibitor&#xD;
Pertuzumab: anti-HER2 monoclonal antibody</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>NCI CTCAE v. 4.03</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nail discoloration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver Function Abnormality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Skin Discoloration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jenny Chang</name_or_title>
      <organization>Houston Methodist</organization>
      <phone>713-441-0681</phone>
      <email>jcchang@houstonmethodist.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

